FANA Oligonucleotides for LINE-1 RNA Suppression in Aging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Loss of heterochromatin during physiological and pathological aging leads to disorganized heterochromatin, which is characterized by the transcriptional activity of LINE-1 retrotransposons, contributing to premature aging and age-related diseases.
Innovation Solution
The use of 2′ fluoroarabinonucleic acid (FANA)-modified oligonucleotides, administered in pharmaceutical compositions, to inhibit or decrease LINE-1 RNA expression, thereby restoring heterochromatin organization and reducing the signs and symptoms of aging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If heterochromatin organization is maintained, then LINE-1 retrotransposon transcriptional activity is suppressed, but during aging heterochromatin is lost leading to increased LINE-1 activity
Solution Approach 1:
The patent applies preliminary anti-action by administering antisense oligonucleotides that specifically target and bind to LINE-1 RNA transcripts before they can be translated into retrotransposon proteins. This prevents the harmful transcriptional activity of LINE-1 elements that would otherwise occur due to age-related heterochromatin loss, thereby counteracting the detrimental effects before they manifest fully
Solution Approach 2:
The patent uses antisense oligonucleotides as intermediary molecules that mediate between the heterochromatin disruption and the harmful LINE-1 expression. These oligonucleotides bind to LINE-1 RNA transcripts, forming RNA-oligonucleotide hybrids that prevent translation and effectively intermediate the pathway between chromatin disorganization and retrotransposon protein production
2Object-generated harmful factors
If LINE-1 retrotransposons are transcriptionally active, then heterochromatin becomes disorganized, but suppressing LINE-1 activity can restore heterochromatin organization
Solution Approach 1:
The patent converts the harmful effect of LINE-1 transcriptional activity into a beneficial outcome by using the LINE-1 RNA transcripts themselves as targets for antisense oligonucleotides. By designing oligonucleotides complementary to LINE-1 RNA sequences, the therapy exploits the presence of these transcripts to deliver suppression, turning the harmful transcriptional activity into the very mechanism for its own control and for restoring heterochromatin organization
3Object-generated harmful factors
If antisense oligonucleotides are used to inhibit LINE-1 RNA, then LINE-1 transcriptional activity is suppressed, but delivery and stability of the oligonucleotides must be optimized
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the oligonucleotides through various modifications including 2′-O-methyl, 2′-O-methoxyethyl, phosphorothioate backbones, and conjugation with cell-penetrating peptides or lipid nanoparticles. These modifications change physical-chemical parameters such as nuclease resistance, cellular uptake efficiency, and half-life, thereby optimizing delivery and stability while maintaining the ability to suppress LINE-1 RNA expression
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oligonucleotides effectively reduce LINE-1 RNA levels, rejuvenate tissues, and reverse premature aging symptoms by enhancing heterochromatin integrity, as demonstrated in various progeria syndromes and age-related diseases.
Implementation Method 1
The antisense oligonucleotides of the invention can inhibit or decrease LINE-1 RNA in a cell
Data Source
AI summary
Methods for decreasing or inhibiting human L1 retrotransposon RNA and compositions for use therein.